Olema Pharmaceuticals, Inc. (OLMA) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Anemia — all grades | 38.00 percent | FY2026-Q1 |
| Neutropenia — all grades | 34.00 percent | FY2026-Q1 |
| Palazestrant patients treated to date | 400.00 | FY2025-Q1 |
| Non-GAAP general and administrative expenses | 5.4M | FY2026-Q2 |
| Non-GAAP research and development expenses | 48.9M | FY2026-Q2 |
| Stock-based compensation expense | 8.89M | FY2026-Q2 |
| General and administrative stock-based compensation expense | 4.01M | FY2026-Q2 |
Back to OLMA overview · OLMA earnings · OLMA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.